Biotech | September 10, 2025
Evonik and Ethris partner to expand offerings for nucleic acid delivery
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
Increases speed to market for drug developers working on nucleic acid therapeutics
Iskra has held leadership positions across Central & Eastern Europe, Eurasia, Middle East & Africa at AstraZeneca
Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
This linear, covalently closed, double-stranded DNA offers a rapid, cell-free alternative to traditional plasmid DNA, addressing a critical bottleneck in nucleic acid therapeutics development
The MAST trial is designed to test whether a single dose of pre-emptive, orally administered EBX-102-02 can protect and restore microbial diversity during transplantation
The conditional, time-limited approval comes through a joint effort with RACTHERA, a joint venture in which Sumitomo Chemical holds a 66.6% stake and Sumitomo Pharma holds 33.4%
Subscribe To Our Newsletter & Stay Updated
